Paper Details
- Home
- Paper Details
Efficacy of Ultralow-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in ABO-Incompatible Kidney Transplantation Recipients.
Author: HwangS D, KimH Y, KimJ H, KimJ K, LeeD Y, LeeJ H, OhJ S, SinY H, SongJ H
Original Abstract of the Article :
Cytomegalovirus (CMV) infection can increase morbidity and mortality in kidney transplant (KT) patients. Chemoprophylaxis with valganciclovir (VGCV) is recommended for ABO-incompatible (ABOi) KT patients as it significantly reduces CMV disease and infection. The recommended dose of VGCV for preventi...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1016/j.transproceed.2018.04.010
データ提供：米国国立医学図書館（NLM）
Protecting Transplant Recipients: A Lifeline in the Desert of Immunity
Kidney transplantation, a life-saving procedure, is a complex journey that often involves navigating the delicate balance of the immune system. This study delves into the world of organ transplantation, specifically exploring the use of valganciclovir (VGCV) as a prophylaxis against cytomegalovirus (CMV) infection in ABO-incompatible kidney transplant recipients.
CMV infection can pose a significant threat to transplant recipients, increasing the risk of morbidity and mortality. The study highlights the importance of CMV prophylaxis, particularly in ABO-incompatible recipients, who are at an increased risk of developing CMV infection.
Valganciclovir: A Protective Oasis
The study confirms the effectiveness of VGCV in preventing CMV disease and infection in ABO-incompatible kidney transplant recipients. However, the study also raises a concern about the cost of VGCV and the possibility of insufficient amounts being administered. The researchers call for strategies to ensure adequate access to this vital medication, ensuring the well-being of transplant recipients.
Navigating the Desert: Transplant Care and Prevention
Kidney transplantation is a delicate journey across the vast desert of the immune system. Protecting transplant recipients from infections like CMV is crucial. This study underscores the importance of preventative measures, ensuring that recipients receive the necessary medications and care to thrive after their transplantation journey.
Dr.Camel's Conclusion
Valganciclovir offers a vital lifeline in the desert of immunity for kidney transplant recipients. This study underscores the importance of preventative measures and raises awareness about the need to ensure adequate access to this essential medication. By working together, we can provide the necessary care and support to protect transplant recipients and ensure their successful journey through the desert of recovery.
Date :
- Date Completed 2018-12-11
- Date Revised 2018-12-11
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.